I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer
I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology company focused on precision immuno-oncology, developing differentiated therapies for cancer.
I-Mab (IMAB)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hillhouse Capital Management Lei Zhang | 5,980,568 | $22,606,547 | 0.55% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 3,338,034 | $12,617,769 | 0.02% | |
| 3. | Ariose Capital Yi Xin | 1,704,393 | $6,442,606 | +1668% | 2.16% |
| 4. | Exome Asset Management Samuel Isaly | 1,439,604 | $5,441,703 | 3.3% | |
| 5. | Siren L.L.C. Raymond Debbane | 1,165,957 | $4,407,317 | 0.17% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,991,377 | $30,287,319 | 0.01% | |
| 2. | 2,232,040 | $8,437,112 | 0% | |
| 3. | 1,132,563 | $4,281,088 | 0.02% | |
| 4. | 561,366 | $2,121,963 | 0.1% | |
| 5. | 395,431 | $1,494,729 | 0% |
News See All
15 Best Biotech Penny Stocks to Invest in Right Now
Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC's "Closing Bell Overtime" in July on whether the biotech industry is ready for a breakthrough.
I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025
I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts.
12 Best Performing NASDAQ Stocks According to Analysts
On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally. Ives stated that he believes they are only at the beginning of...
I-Mab (NASDAQ:IMAB) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call. At this time, all participants are in listen-only mode.
I-Mab (NASDAQ:IMAB) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call. At this time, all participants are in listen-only mode.
Ray Dalio on Potential US-China War and Rise of China
In this article, we discuss Ray Dalio on potential US China war and rise of China.
I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript
Tyler Ehler: Good morning, everyone, and thank you for joining us this morning and for standing by.
I-Mab (NASDAQ:IMAB) Q4 2022 Earnings Call Transcript
Tyler Ehler: Good morning to everyone and thank you for joining us this morning. Thank you all for standing by.
10 52-Week Low Stocks to Buy Now
The 52-week low for a stock reflects the least closing price the security has traded at over a 52-week timeline.